Julie Braish, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji. "Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes." Blood (2025). https://doi.org/10.1182/blood-2025-240